Axon Enterprise, Inc. (NASDAQ:AXON – Get Free Report) Director Julie A. Cullivan sold 1,261 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $682.06, for a total value of $860,077.66. Following the completion of the transaction, the director now directly owns 2,392 shares of the company’s stock, valued at approximately $1,631,487.52. This trade represents a 34.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Axon Enterprise Stock Performance
Shares of AXON stock opened at $687.69 on Friday. The business’s 50 day simple moving average is $516.24 and its 200 day simple moving average is $393.00. Axon Enterprise, Inc. has a one year low of $232.78 and a one year high of $698.67. The stock has a market capitalization of $52.44 billion, a PE ratio of 177.70, a PEG ratio of 15.13 and a beta of 1.01. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.96 and a quick ratio of 2.63.
Institutional Trading of Axon Enterprise
Institutional investors have recently added to or reduced their stakes in the stock. Quent Capital LLC boosted its holdings in Axon Enterprise by 1,875.0% in the third quarter. Quent Capital LLC now owns 79 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 75 shares during the last quarter. Prestige Wealth Management Group LLC boosted its holdings in Axon Enterprise by 115.8% in the third quarter. Prestige Wealth Management Group LLC now owns 82 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 44 shares during the last quarter. Blue Trust Inc. boosted its holdings in Axon Enterprise by 987.5% in the second quarter. Blue Trust Inc. now owns 87 shares of the biotechnology company’s stock valued at $27,000 after acquiring an additional 79 shares during the last quarter. Brooklyn Investment Group bought a new stake in Axon Enterprise in the third quarter valued at approximately $41,000. Finally, Planning Capital Management Corp boosted its holdings in Axon Enterprise by 83.3% in the third quarter. Planning Capital Management Corp now owns 121 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 55 shares during the last quarter. 79.08% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Read Our Latest Stock Report on Axon Enterprise
About Axon Enterprise
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Stories
- Five stocks we like better than Axon Enterprise
- What is a buyback in stocks? A comprehensive guide for investors
- Fast-Growing Companies That Are Still Undervalued
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Top Cybersecurity Stock Picks for 2025
- Why Are Stock Sectors Important to Successful Investing?
- Archer or Joby: Which Aviation Company Might Rise Fastest?
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.